Source comparison
Kisspeptin Dosing Strategies: Continuous Infusion vs Bolus Administration
The single most predictive variable in kisspeptin fertility outcomes isn't total dose. It's whether the peptide is administered as pulsatile stimulation or sustained elevation. GnRH neurons respond to kisspeptin in a dose-dependent manner, but the response pat
This comparison does not assign a generated winner or score.
- The single most predictive variable in kisspeptin fertility outcomes isn't total dose. It's whether the peptide is administered as pulsatile stimulation or sustained elevation. GnRH neurons respond to kisspeptin in a dose-dependent manner, but the response pattern (acute LH surge vs sustained pulsatility) determines downstream reproductive outcomes.
- Continuous IV infusion at 0.01–0.04 nmol/kg/hour restores physiologic GnRH pulsatility in women with hypothalamic amenorrhea. A 2019 trial at Massachusetts General Hospital demonstrated resumption of menstrual cycles in 78% of participants after 12 weeks of pulsatile kisspeptin administration. This mirrors endogenous kisspeptin secretion from the arcuate nucleus, where KISS1 neurons fire in synchronised bursts every 60–90 minutes to drive the GnRH pulse generator. The infusion protocol mimics this pattern without triggering receptor desensitisation, which occurs at sustained high concentrations above 2 nmol/kg/hour.
- Bolus administration. Typically 1.6 to 6.4 nmol/kg as a single IV push. Produces an acute LH surge within 30–60 minutes, peaking at 4–6 hours post-injection. This protocol is used in IVF cycles to replace hCG for final oocyte maturation, with a 2021 Cochrane review finding comparable live birth rates but 60% reduction in ovarian hyperstimulation syndrome (OHSS) risk compared to standard hCG trigger protocols. The mechanism: kisspeptin's shorter half-life (approximately 28 minutes for kisspeptin-54) means LH elevation is transient rather than sustained, reducing corpus luteum overstimulation.
- Our experience tracking published protocols reveals a consistent pattern: researchers who attempt bolus dosing for conditions requiring pulsatile stimulation (like hypothalamic amenorrhea) report poor outcomes, while those using continuous infusion for ovulation triggering see delayed or absent LH peaks. The dosing strategy must match the intended HPG axis correction.